Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
Mikkael A. Sekeres, Justin M. Watts, Atanas Radinoff, Montserrat Arnán Sangerman, Marco Cerrano, Patricia Font, Joshua F. Zeidner, María Díez‐Campelo, Carlos Graux, Jane L. Liesveld, Dominik Selleslag, Nikolay Tzvetkov, Robert J. Fram, Dan Zhao, Jill A. Bell, Sharon Friedlander, Douglas V. Faller, Lionel Adès
Abstract
TO THE EDITOR : There is a critical unmet need for novel treatments for higher-risk myelodysplastic syndromes (MDS), higher-risk chronic myelomonocytic leukemia (CMML), and low-blast (LB) acute myeloid leukemia (AML). For patients ineligible for stem cell transplant (SCT), standard therapy with hypomethylating agents, such as azacitidine and decitabine, is not curative, with most patients relapsing within 2 years. [...]
Topics & Concepts
AzacitidineInternal medicineMyelodysplastic syndromesRandomized controlled trialMedicineOncologyHypomethylating agentBiologyBone marrowGeneticsDNA methylationGene expressionGeneAcute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors ResearchProtein Degradation and Inhibitors